EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Jeysson E Mejía-Guzmán, Ramón A Belmont-Hernández, Norberto C Chávez-Tapia iD, Misael Uribe iD, Natalia Nuño-Lámbarri

International Journal of Molecular Sciences · 25.03.2025 · 26 (7) · 2959

DOI: 10.3390/ijms26072959 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.03.2025. Verfasst von Jeysson E Mejía-Guzmán und 4 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medica Sur Clinic and Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a highly prevalent metabolic disorder characterized by hepatic steatosis in conjunction with at least one cardiometabolic risk factor, such as obesity, type 2 diabetes, hypertension, or dyslipidemia. As global rates of obesity and metabolic syndrome continue to rise, MASLD is becoming a major public health concern, with projections indicating a substantial increase in prevalence over the coming decades. The disease spectrum ranges from simple steatosis to metabolic-dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma, contributing to significant morbidity and mortality worldwide. This review delves into the molecular mechanisms driving MASLD pathogenesis, including dysregulation of lipid metabolism, chronic inflammation, oxidative stress, mitochondrial dysfunction, and gut microbiota alterations. Recent advances in research have highlighted the role of genetic and epigenetic factors in disease progression, as well as novel therapeutic targets such as peroxisome proliferator-activated receptors (PPARs), fibroblast growth factors, and thyroid hormone receptor beta agonists. Given the multifaceted nature of MASLD, a multidisciplinary approach integrating early diagnosis, molecular insights, lifestyle interventions, and personalized therapies is critical. This review underscores the urgent need for continued research into innovative treatment strategies and precision medicine approaches to halt MASLD progression and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansAnimalsOxidative StressLipid MetabolismGastrointestinal Microbiome

Stichwörter der Autor:innen

MASLDbiomarkerschronic inflammationemerging therapieslipogenesisoxidative stress

Autor:innen und Institutionen

  • Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico.
  • Postgraduate Program in Experimental Biology, División de Ciencias Básicas y de la Salud (DCBS), Universidad Autonoma Metropolitana-Iztapalapa, Mexico City 09340, Mexico.
  • Obesity and Digestive Diseases Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico.
  • Surgery Department, Faculty of Medicine, The National Autonomous University of Mexico (UNAM), Mexico City 04510, Mexico.

ORCID-Profile: Norberto C Chávez-Tapia, Misael Uribe

Förderung

  • Medica Sur Clinic and Foundation

Zitieren

APA

Mejía-Guzmán, J. E., Belmont-Hernández, R. A., Chávez-Tapia, N. C., Uribe, M., & Nuño-Lámbarri, N. (2025). Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies. International Journal of Molecular Sciences, 26(7), 2959. https://doi.org/10.3390/ijms26072959

Vancouver

Mejía-Guzmán JE, Belmont-Hernández RA, Chávez-Tapia NC, Uribe M, Nuño-Lámbarri N. Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. 2025;26(7):2959. doi:10.3390/ijms26072959

BibTeX
@article{MejaGuzmn2025,
  author = {Mejía-Guzmán, Jeysson E and Belmont-Hernández, Ramón A and Chávez-Tapia, Norberto C and Uribe, Misael and Nuño-Lámbarri, Natalia},
  title = {Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {7},
  pages = {2959},
  doi = {10.3390/ijms26072959}
}
Kostenlos starten →